Could an allergy drug boost lung cancer treatment?
NCT ID NCT07358689
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests whether adding an allergy medicine (diphenhydramine) to standard chemo and immunotherapy (toripalimab) helps shrink lung cancer before surgery and prevent it from coming back after. About 120 people with stage IIA-IIIB non-small cell lung cancer will be randomly assigned to get the allergy drug or not. The main goal is to see if the cancer disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.